Loading clinical trials...
Loading clinical trials...
A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
Conditions
Interventions
Golimumab 50 mg
Mavrilimumab 100 mg
Locations
39
Argentina
Research Site
Ciudad Autonoma Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
San Miguel de Tucumán, Argentina
Research Site
Barranquilla, Colombia
Research Site
Prague, Czechia
Research Site
Uherské Hradiště, Czechia
Start Date
March 1, 2013
Primary Completion Date
November 1, 2014
Completion Date
February 1, 2015
Last Updated
October 31, 2016
NCT06647069
NCT07484243
NCT06841562
NCT07268326
NCT07233655
NCT07029555
Lead Sponsor
MedImmune LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions